Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
PlatinumCode launched an e-commerce website that provides in-depth descriptions of product lines to assist customers in making educated decisions regarding their purchase. The site also offers product-specific landing pages that speak to the features and benefits of the product, as well as the variety of packaging options.
QuantuMDx explored licensing opportunities for its rapid DNA extraction kit Q-PREP at BIO in Philadelphia, which took place in mid-June. Q-PREP is a next-generation DNA extraction technology set to dramatically shorten and simplify the molecular workflow for polymerase chain reaction, sequencing, and other molecular processes. The technology is presently being deployed in next-generation spin columns.
Fluxion Biosciences and Swift Biosciences announced a jointly developed workflow for oncology clinical research designed to detect somatic mutations from a routine blood draw. The workflow uses Fluxion’s IsoFlux System for circulating tumor cell enrichment and Swift’s Accel-Amplicon technology for high-sensitivity variant detection using low starting inputs.
Magellan Diagnostics received FDA 510(k) clearance to market its LeadCare Plus Blood Lead Testing System in the U.S. for the quantification of lead levels in blood.
BioTek released the Synergy Neo2 Multi-Mode Reader, which is designed for speed and ultra-high performance and incorporates BioTek’s patented Hybrid Technology with independent optical paths. Continuously variable bandwidth quadruple monochromators, sensitive high transmission filter-based optics, and up to four photomultiplier tubes provide fast measurements with excellent results, according to a company statement.
New England Biolabs released the NEBNext Library Quant Kit for Illumina, a qPCR-based solution for accurate next-generation sequencing library quantitation.
Total Lab Care’s Laboratory Essentials course has been approvedT for 3.5 hours of P.A.C.E. continuing education credits. This Web-based interactive training program comprises 10 individual lessons and reviews CLIA rules and regulations and laboratory operations from preanalytical to postanalytical processes, including laboratory testing requirements (pipetting, safety, equipment operation, etc.).
Medtronic offers the GenCut core biopsy system, a lung tissue biopsy tool for use with the SuperDimension navigation system, which enables a minimally invasive approach to accessing difficult-to-reach areas of the lung.
Biocartis and Fast-track Diagnostics have entered into a strategic collaboration to develop a range of multiplex infectious disease tests to run on the Biocartis Idylla system. The two companies plan to collaborate on a new approach to infectious disease diagnostics, “syndromic multiplex testing,” which enables the identification of a broad range of disease pathogens in a single test.
DiaSorin and Beckman Coulter Diagnostics have signed a distribution partnership agreement for the commercialization in China of DiaSorin Hepatitis B, C, and HIV tests on DiaSorin’s Liaison XL LAS connected to Beckman Coulter’s Power Express and Power Processor automated sample processing systems.
